Merck Aktie 10683053 / US58933Y1055
104.94
USD
-0.57
USD
-0.54%
22:00:01
NDN
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.88 |
| Vanguard Group, Inc. (Subfiler) | 8.53 |
| State Street Corp. | 4.65 |
| BlackRock Fund Advisors | 3.23 |
| Vanguard Total Stock Market Index Fund | 3.08 |
| Wellington Management Co. LLP | 2.45 |
| Vanguard 500 Index Fund | 2.32 |
| BlackRock Institutional Trust Co. NA | 2.24 |
| Geode Capital Management LLC | 1.91 |
| Charles Schwab Investment Management, Inc. | 1.18 |
| Fidelity 500 Index Fund | 1.09 |
| SPDR S&P 500 ETF Trust | 1.08 |
| T. Rowe Price Associates, Inc. (Investment Management) | 1.04 |
| Norges Bank (13F) | 0.97 |
| Government Pension Fund - Global (The) | 0.95 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 69'000 | 71'000 | 74'000 | 68'000 | 69'000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.62 | 0.66 | 0.65 | 0.72 | 0.85 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 25'875 | 27'483 | 27'764 | 30'266 | 35'722 |
| Summe Anlagevermögen | 51'815 | 53'257 | 58'770 | 72'815 | 77'976 |
| Summe Aktiva | 82'637 | 84'397 | 91'588 | 105'694 | 109'160 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 25'114 | 27'350 | 33'453 | 34'631 | 31'985 |
| Summe Fremdkapital | 55'755 | 58'396 | 66'184 | 67'437 | 63'102 |
| Summe Eigenkapital | 26'882 | 26'001 | 25'404 | 38'257 | 46'058 |
| Summe Passiva | 82'637 | 84'397 | 91'588 | 105'694 | 109'160 |
Adresse
| 2000 Galloping Hill Road, 07033 Kenilworth | |
| Telefon | +1 (908) 740-4000 |
| URL | http://www.merck.com |
Management
|
Allan Gabor
President-Asian-Pacific-BioPharma Business |
|
Andre Musto
SVP & Head-Gbl Cardiometabolic & Endoc Franchise |
|
Brooke Hinkson
Executive Director-Global Clinical Data Standards |
|
Carol Bowden
Med Aff. Dir, Cardiovascular Metabolism, NorCal |
|
Caroline A. Litchfield
Chief Financial Officer & Executive Vice President |
|
Chirfi Guindo
Chief Marketing Officer-Human Health & SVP |
|
Christine E. Seidman
Independent Director |
|
Dave Williams
Chief Information & Digital Officer |
|
Dean Y. Li
EVP & President-Merck Research Laboratories |
|
Denise Williams
Vice President |
|
Douglas M. Baker
Independent Director |
|
Eric H. Rubin
Senior VP-Global Clinical Oncology |
|
Fiona Hamilton Marshall
Senior VP & Global Head-Discovery Sciences |
|
Inge G. Thulin
Independent Director |
|
Jacks Lee
Senior Vice President-Manufacturing & Supply |
|
James Matteucci
Associate Director-State Government Affairs |
|
Jannie Oosthuizen
President-Merck Human Health |
|
Jennifer Zachary
Executive Vice President & General Counsel |
|
Johanna Herrmann
Vice President-Global Communications |
|
Joseph Romanelli
President-Human Health International |
|
Kathy J. Warden
Independent Director |
|
Kelly E. W. Grez
Secretary |
|
Lisa LeCointe-Cephas
Senior VP, Chief Ethics & Compliance Officer |
|
Mary Ellen Coe
Independent Director |
|
Michael Klobuchar
Chief Strategy Officer & Executive Vice President |
|
Pamela J. Craig
Independent Director |
|
Patricia Fiorello Russo
Independent Director |
|
Paul B. Rothman
Independent Director |
|
Peter C. Wendell
Independent Director |
|
Peter Dannenbaum
Vice President-Investor Relations |
|
Richard R. DeLuca
Executive Vice President & President-Animal Health |
|
Risa J. Lavizzo-Mourey
Independent Director |
|
Rita A. Karachun
Senior Vice President-Finance & Global Controller |
|
Robert M. Davis
Chairman, President & Chief Executive Officer |
|
Sanat Chattopadhyay
EVP & President-Merck Manufacturing Division |
|
Stephen L. Mayo
Independent Director |
|
Steven C. Mizell
Chief Human Resources Officer & Executive VP |
|
Sylvia A. Ayler
Legal Director |
|
Thomas Henry Glocer
Lead Independent Director |
